HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
2期
进行中（已停止招募）
NCT04619004
| 适应症 | Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Daiichi Sankyo |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 277 人 |
|---|
| 干预（药物） | Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration) |
|---|
| 开始日期 | 2021年2月2日 |
|---|
| 完成日期 | 2022年11月21日 |
|---|
| 结果公布日 | 2024年4月2日 |
|---|
摘要
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months · Participants
| Patritumab Deruxtecan 5.6 mg/kg | 64 Participants |
|---|
| Patritumab Deruxtecan Up-Titration | 8 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。